Analyst Reco. Amylyx Pharmaceuticals, Inc.

Equities

AMLX

US03237H1014

Real-time Estimate Cboe BZX Other stock markets 17:55:42 29/04/2024 BST			5-day change	1st Jan Change
1.875 ^USD	+6.53%		-5.05%	-87.23%

04-11	Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating	MT
04-10	Transcript : Amylyx Pharmaceuticals, Inc. - Special Call

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating	04-11	MT
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $4 From $8, Maintains Buy Rating	04-05	MT
Mizuho Downgrades Amylyx Pharmaceuticals to Neutral From Buy After Negative Results From Phase 3 PHEONIX Study, Adjusts PT to $4 From $32	03-18	MT
H.C. Wainwright Adjusts Price Target on Amylyx Pharmaceuticals to $8 From $42, Maintains Buy Rating	03-12	MT
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $8 From $36, Maintains Buy Rating	03-11	MT
Goldman Sachs Downgrades Amylyx Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $4 From $40	03-11	MT
Leerink Partners Downgrades Amylyx Pharmaceuticals to Market Perform From Outperform	03-11	MT
Baird Downgrades Amylyx Pharmaceuticals to Neutral From Outperform, Cuts Price Target to $4 From $37	03-11	MT
Mizuho Securities Ups Price Target on Amylyx Pharmaceuticals to $32 From $27 on New Revenue Contributions by PSP, Wolfram Therapies, Keeps Buy Rating	03-08	MT
Baird Starts Amylyx Pharmaceuticals With Outperform Rating, $37 Price Target	01-03	MT
Mizuho Slashes Price Target on Amylyx Pharmaceuticals to $27 From $46, Keeps Buy Rating	12-21	MT
Deutsche Bank Initiates Coverage on Amylyx Pharmaceuticals With Buy Rating, $36 Price Target	12-12	MT
Goldman Sachs Adjusts Price Target on Amylyx Pharmaceuticals to $40 From $46, Maintains Buy Rating	11-10	MT
HC Wainwright Adjusts Price Target on Amylyx Pharmaceuticals to $42 From $50, Keeps Buy Rating	11-10	MT
Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $46 From $48, Keeps Buy Rating	19/10/23	MT
Goldman Sachs Upgrades Amylyx Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $49 From $45	24/07/23	MT
Mizuho Securities Cuts Amylyx Pharmaceuticals' Price Target to $50 From $52, Buy Rating Kept	12/05/23	MT
Citigroup Trims Amylyx Pharmaceuticals' Price Target to $53 From $54, Buy Rating Kept	12/05/23	MT
Goldman Sachs Cuts Amylyx Pharmaceuticals' Price Target to $45 From $47, Neutral Rating Kept	12/05/23	MT
Mizuho Initiates Amylyx Pharmaceuticals at Buy With $52 Price Target	31/03/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Amylyx Pharmaceuticals, Inc.

Equities

AMLX

US03237H1014

Analyst Reco.

Filters